Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study)

European Journal of Heart Failure

Volumn 4, Issue 5, 2002, Pages 647-654

  Echemann, M ^a   Alla, F ^a   Briancon S ^a   Juilliere Y ^a   Virion, J M ^a   Mertes P M ^a   Villemot, J P ^a   Zannad, F ^a,b,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Participating Hospitals in Lorraine   (France)

Author keywords

Antithrombotic treatment; Epidemiology; Severe heart failure; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; DIAZOXIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; INSULIN; MINOXIDIL; MOLSIDOMINE; NICORANDIL; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; ORAL ANTIDIABETIC AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SPIRONOLACTONE; VASODILATOR AGENT; WARFARIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL OBSERVATION; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; DATA BASE; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; FRANCE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PERIPHERAL EDEMA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SODIUM BLOOD LEVEL; STATISTICAL MODEL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ASPIRIN; CONTROLLED CLINICAL TRIALS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; FRANCE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036802114     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00028-4     Document Type: Article

References (23)

1. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
2. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999;138:87-94.
3. Rodeheffer RJ, Jacobsen SJ, Gersch BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993;68:1143-50.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS). N Engl J Med 1986;314:1547-52.
5. Saxon L, Stevenson WG, Middlekauff HR, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1993;72:62-5.
6. Zannad F, Briançon S, Juillière Y, et al. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: The EPICAL study. J Am Coll Cardiol 1999;33:734-42.
7. Jaffri SM, Cleland J, Massie M. Is there a role for warfarin or aspirin therapy in heart failure? Heart Fail Rev 1997;1:271-6.
8. Cowie M, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25.
9. Koniaris L, Goldhaber S. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998;31:745-8.
10. Nguyen K, Aurnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-9.
11. Dixon WJ. BMDP Statistical Software Manual. Berkeley, California: University of California Press, 1992.
12. Al-Khadra A, Salem D, Rand W, Udelson J, Smith J, Konstam M. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998;31:749-53.
13. Cleland JG, Bulpitt CJ, Falk RH, Findley IN, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-9.
14. Cowburn PJ, Cleland JGF, Coats AJS, Komadja M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696-710.
15. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
16. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
17. Al-Khadra A, Salem D, Rand W, Udelson J, Smith J, Konstam M. Antiplatelet agents and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
18. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction predicts stroke following myocardial infarction. N Engl Med 1997;336:251-7.
19. Echemann M, Zannad F, Briançon S, et al. Determinants of angiotensin-converting enzyme inhibitors prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study. Am H J 2000;139:624-31.
20. Pullicino PM, Halperin JL, Thompson JLP. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000;54:288-94.
21. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997;79:909-13.
22. Cokkinos DV, Toutouzas PK. Antithrombotic therapy in heart failure: A randomized comparison of warfarin vs. aspirin (HELAS). Eur J of Heart Fail 1999;1:419-23.
23. Gibbs CR, Davies MK, Lip GYH. ABC of heart failure. Management: Digoxin and other inotropes, β blockers, and antiarrhythmic and antithrombotic treatment. BMJ 2000;320:495-8.